Expression of a specific extracellular matrix signature is a favorable prognostic factor in acute myeloid leukemia

https://doi.org/10.1016/j.lrr.2017.12.001Get rights and content
Under a Creative Commons license
open access

Highlights

  • Extracellular matrix (ECM) expression in acute myeloid leukemia predicts relapse.

  • The ECM-signature is small, with only 15 genes.

  • High ECM-signature expression indicates an overall favorable outcome.

  • High ECM-signature expression predicts therapeutic stage-specific outcome.

  • ECM-signature expression works in RT-qPCR and microarrays.

Abstract

Relapse of acute myeloid leukemia (AML) is still dramatically frequent, imposing the need for early markers to quantify such risk. Recent evidence point to a prominent role for extracellular matrix (ECM) in AML, but its prognostic value has not yet been investigated. Here we have investigated whether the expression of a 15-ECM gene signature could be applied to clinical AML research evaluating a retrospective cohort of 61 AML patients and 12 healthy donors. Results show that patients whose ECM signature expression is at least twice as that of healthy donors have considerably longer relapse-free survival, with further stage-specific therapy outcomes.

Keywords

Extracellular matrix (ECM)
Acute myeloid leukemia (AML)
Hematopoiesis
Clinical study
PCR

Cited by (0)